secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keros Therapeutics, Inc. (KROS)
CIK:        0001664710
Form:       8-K
Filed at:   2024-09-30T23:59:59+00:00
Accession:  0001664710-24-000078
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Keros completes Phase 2 PAH trial TROPOS enrollment with 113 patients; topline Q2 2025
--------------------------------------------------------------------------------

- Completed enrollment of TROPOS Phase 2 trial of cibotercept (KER-012) for pulmonary arterial hypertension.
- Enrolled 113 patients, exceeding the initial target of 90 patients.
- Topline data expected to be presented in the second quarter of 2025.
- Trial evaluates cibotercept in combination with background therapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1664710/000166471024000078/0001664710-24-000078-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1664710/000166471024000078/kros-20240930.htm
  HTML page:      https://secwatch.observer/filing/0001664710-24-000078

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer